Top

International Urology and Nephrology

Published in:

01-02-2017 | Nephrology - Original Paper

Assessment of the relationship between serum paraoxonase activity and epicardial adipose tissue in hemodialysis patients

Authors: Emad Abdallah, Samya El-Shishtawy, Nevine Sherif, Ahmed Ali, Omnia El-Bendary

Published in: International Urology and Nephrology | Issue 2/2017

Abstract

Purpose

Paraoxonase-1 (PON-1) is a high-density lipoprotein-associated (HDL) enzyme, which has been shown to reduce susceptibility to low-density lipoprotein (LDL) peroxidation. Epicardial adipose tissue (EAT) is a marker of atherosclerosis. The aim of this study was to determine the relationship between PON-1 activity and EAT in hemodialysis (HD) patients.

Methods

This is a cross-sectional study conducted on 72 (43 males) HD patients with end-stage renal disease. Serum levels for lipid profiles, C-reactive protein, calcium, phosphate, and parathyroid hormone were measured. PON-1 activity was also measured and compared to the rate of enzymatic hydrolysis of paraoxon to p-nitrophenol. Echocardiography was used to measure EAT thickness (EATT). The correlation between PON-1 and EATT was assessed, while independent predictors of EATT in HD patients were similarly assessed using multivariate regression analysis.

Results

There was a significant low mean value of PON-1 activity in HD patients compared with the control group (82.1 ± 31.6 vs. 164.3 ± 61.5 U/l, p = 0.0001) and significant high mean value of EATT in HD patients, compared with controls (6.2 ± 1.7 vs. 3.9 ± 1.1 mm, p = 0.0001). In addition, there was a significant negative correlation between PON-1 activity and EATT (r = −0.484, p = 0.0001) and a significant positive correlation between PON-1 activity and HDL-C (r = 0.417, p = 0.0003). PON-1, total cholesterol, triglycerides, LDL, HDL, age, and body mass index were found to be independent predictors of EATT.

Conclusion

Our study demonstrated that PON-1 activity was significantly lower in HD patients compared with healthy controls and that PON-1 activity was inversely correlated with EATT in this population.

Hou FF, Jiang JP, Chen J, Yu X, Zhou Q, Chen P, Mei C, Xiong F, Shi W, Zhou W, Liu X, Sun S, Xie D, Liu J, Zhang P, Yang X, Zhang Y, Zhang Y, Liang X, Zhang Z, Lin Q, Yu Y, Wu S, Xu X (2012) China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis. BMC Nephrol 13(1):94–102CrossRefPubMedPubMedCentral

Kosaka T, Yamaguchi M, Motomura T, Mizuno K (2005) Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta 359:156–162CrossRefPubMed

Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C (1998) Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 9(11):2082–2088PubMed

Beltowski J, Wójcicka G, Jamroz A (2003) Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 170:21–29CrossRefPubMed

Senti M, Tomás M, Elosual R, Sala J (2002) The paraoxonase-1 codon 192 polymorphism is associated with fasting total cholesterol and LDL-cholesterol concentrations only in postmenopausal women. The REGICOR study. Clin Chem Lab Med 40:677–683CrossRefPubMed

Iacobellis G, Corradi D, Sharma AM (2005) Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2:536–543CrossRefPubMed

Corradi D, Maestri R, Callegari S, Pastori P, Goldoni M, Luong TV, Bordi C (2004) The ventricular epicardial fat is related to the myocardial mass in normal, ischemic and hypertrophic hearts. Cardiovasc Pathol 13:313–316CrossRefPubMed

Rabkin SW (2014) The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis. Metab Syndr Relat Disord 12(1):31–42CrossRefPubMed

Turan MN, Gungor O, Asci G, Kircelli F, Acar T, Yaprak M, Ceylan N, Demirci MS, Bayraktaroglu S, Toz H, Ozkahya M, Ok E (2013) Epicardial adipose tissue volume and cardiovascular disease in hemodialysis patients. Atherosclerosis 226(1):129–133CrossRefPubMed

10.

Turkmen K, Ozbek O, Kayrak M, Samur C, Guler I, Tonbul HZ (2013) Peri-aortic fat tissue thickness in peritoneal dialysis patients. Perit Dial Int 33(3):316–324CrossRefPubMedPubMedCentral

11.

Spencer K (1986) Analytical reviews in clinical biochemistry: the estimation of creatinine. Ann Clin Biochem 23:1–25CrossRefPubMed

12.

Zein N, Ganuza C, Kushner I (1979) Significance of C-reactive protein elevation in patients with SLE. Arthritis Rheum 22:7–12CrossRefPubMed

13.

Suchocka Z, Swatowska J, Pachecka J, Suchocka P (2006) RP-HPLC determination of paraoxonase activity in human blood serum. J Pharm Biomed Anal 42:113–119CrossRefPubMed

14.

Bertaso AG, Bertol D, Duncan BB, Foppa M (2013) Epicardial fat definition, measurements and systematic review of main outcomes. Arq Bras Cardiol 101(1):e18–e28PubMedPubMedCentral

15.

Nusair MB, Rajpurohit N, Alpert MA (2012) Chronic inflammation and coronary atherosclerosis in patients with end-stage renal disease. Cardiorenal Med 2:117–124CrossRefPubMedPubMedCentral

16.

Moradi H, Pahl MV, Elahimehr R, Vaziri ND (2009) Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153:77–85CrossRefPubMed

17.

Pahl MV, Ni Z, Sepassi L, Moradi H, Vaziri ND (2009) Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD). Nephrol Dial Transplant 24:2541–2546CrossRefPubMedPubMedCentral

18.

Moradi H, Said HM, Vaziri ND (2013) Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Transl Res 161:477–485CrossRefPubMed

19.

Çolak H, Kilicarslan B, Tekce H, Tanrisev M, Tugmen C, Aktas G, Kursat S (2015) Relationship between epicardial adipose tissue, inflammation and volume markers in hemodialysis and transplant patients. Ther Apher Dial 19(1):56–62CrossRefPubMed

20.

Dirican M, Akca R, Sarandol E, Dilek K (2004) Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 17(6):813–818PubMed

21.

Saeed SA, Elsharkawy M, Elsaeed K, Fooda O (2008) Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int 12(4):471–479CrossRefPubMed

22.

Sztanek F, Seres I, Harangi M, Lo′′csey L, Padra J, Paragh GJR, Asztalos L, Paragh G (2012) Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease. Nephrol Dial Transplant 27(7):2866–2872CrossRefPubMed

23.

Sumegová K, Blažíček P, Fuhrman B, Waczulíková I, Ďuračková Z (2006) Paraoxonase 1 (PON1) and its relationship to lipid variables, age and gender in healthy volunteers. Biologia 61(6):699–704CrossRef

24.

Hasselwander O, Dorothy MM, Fogarty DG, Maxwell AP, Nicholls DP, Young IS (1998) Serum Paraoxonase1 (PON1) and platelet activating factor acetylhydrolase in chronic renal failure. Clin Chem 44:179–181PubMed

25.

Gugliucci A, Kinugasa E, Kotani K, Caccavello R, Kimura S (2011) Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med 49:61–67CrossRefPubMed

26.

Altun B, Tasolar H, Eren N, Binnetoğlu E, Altun M, Temiz A, Gazi E, Barutcu A, Altunoren O, Colkesen Y, Uysal F (2014) Epicardial adipose tissue thickness in hemodialysis patients. Echocardiography 31(8):941–946CrossRefPubMed

27.

Macunluoglu B, Atakan A, Ari E, Kaya Y, Kaspar C, Demir H, Alp HH (2014) Epicardial fat tissue thickness is correlated with diminished levels of co-enzyme Q10, a major antioxidant molecule among hemodialysis patients. Clin Biochem 47(13–14):1231–1234CrossRefPubMed

28.

Atakan A, Macunluoglu B, Kaya Y, Ari E, Demir H, Asicioglu E, Kaspar C (2014) Epicardial fat thickness is associated with impaired coronary flow reserve in hemodialysis patients. Hemodial Int 18(1):62–69CrossRefPubMed

29.

Graham-Brown MPM, McCann GP, Burton JO (2015) Epicardial adipose tissue in patients with end-stage renal disease on haemodialysis. Curr Opin Nephrol Hypertens 24(6):517–524CrossRefPubMed

30.

Turan MN, Gungor O, Asci G, Kircelli F, Acar T, Yaprak M, Ceylan N, Demirci MS, Bayraktaroglu S, Toz H, Ozkahya M, Ercan OK (2013) Epicardial adipose tissue volume and cardiovascular disease in hemodialysis patients. Atherosclerosis 226(1):129–133CrossRefPubMed

31.

Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M (2003) Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 34(6):774–784CrossRefPubMed

32.

Demir B, Demir E, Acıksarı G, Uygun T, Utku IK, Gedikbasi A, Caglar IM, Pirhan O, Tureli HO, Oflar E, Ungan I, Ciftci S, Karakaya O (2014) The association between the epicardial adipose tissue thickness and oxidative stress parameters in isolated metabolic syndrome patients: a multimarker approach. Int J Endocrinol 2014:1–9CrossRef

33.

Rector RS, Warner SO, Liu Y, Hinton PS, Sun GY, Cox RH, Stump CS, Laughlin MH, Dellsperger KC, Thomas TR (2007) Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab 293:E500–E506CrossRefPubMedPubMedCentral

34.

Eroglu E, Kocyigit I, Unal A, Korkar H, Karakukcu C, Orscelik O, Sipahioglu MH, Tokgoz B, Oymak O (2015) Serum paraoxonase activity is associated with epicardial fat tissue in renal transplant recipients. Int Urol Nephrol 47(8):1409–1414CrossRefPubMed

35.

Saruhan E, Olgun A, Oztürk K, Akman S, Erbil MK (2007) Age-related paraoxonase activity changes in Turkish population. Ann N Y Acad Sci 1100:218–222CrossRefPubMed

Title: Assessment of the relationship between serum paraoxonase activity and epicardial adipose tissue in hemodialysis patients
Authors: Emad Abdallah
Samya El-Shishtawy
Nevine Sherif
Ahmed Ali
Omnia El-Bendary
Publication date: 01-02-2017
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 2/2017
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-016-1465-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2017

MicroRNA-155-induced T lymphocyte subgroup drifting in IgA nephropathy

Clinical significance of incidentally detected bladder wall thickening on computed tomography

Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients

Vascular access registry of Serbia: a 4-year experience

Modified laparoscopic simple enucleation with single-layer suture technique versus standard laparoscopic partial nephrectomy for treating localized renal cell carcinoma

Erratum to: Vascular access registry of Serbia: a 4-year experience

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials